advertisement
Abstract #127751 Published in IGR 25-3
Ologen-Augmentation of Ahmed Valves in Pediatric Glaucomas: 2- to 6-Year Follow-Up
Jacobson A; Bohnsack BLOphthalmology. Glaucoma 2025; 8: 609-615
PURPOSE: Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma. DESIGN: Retrospective interventional case series. SUBJECTS: Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up. METHODS: Placement of OAGD between 2018 and 2022. MAIN OUTCOME MEASURES: Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications). RESULTS: Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively. CONCLUSIONS: Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
Full article